• Accueil >
  • Publications >
  • Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

1 août 2018Nature Medicine

DOI : 10.1038/s41591-018-0115-6

Auteurs

Lynn Quek, Muriel D. David, Alison Kennedy, Marlen Metzner, Michael Amatangelo, Alan Shih, Bilyana Stoilova, Cyril Quivoron, Maël Heiblig, Christophe Willekens, Véronique Saada, Samar Alsafadi, M. S. Vijayabaskar, Andy Peniket, Oliver A. Bernard, Sam Agresta, Katharine Yen, Kyle MacBeth, Eytan Stein, George S. Vassiliou, Ross Levine, Stephane De Botton, Anjan Thakurta, Virginie Penard-Lacronique, Paresh Vyas